These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10986065)

  • 1. Survival gain in cost-effectiveness studies.
    Trippoli S; Vaiani M; Messori A; Tendi E
    J Clin Oncol; 2000 Sep; 18(18):3318. PubMed ID: 10986065
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
    Crott R; Ali F; Burdette-Radoux S
    Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
    Desch CE; Hillner BE; Smith TJ; Retchin SM
    J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness, chemotherapy, and the clinician.
    Griggs JJ; Sorbero ME
    Breast Cancer Res Treat; 2009 Apr; 114(3):597-8. PubMed ID: 18695985
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicines: effectiveness or cost.
    Blockman M
    S Afr Med J; 2009 Jan; 99(1):11. PubMed ID: 19374077
    [No Abstract]   [Full Text] [Related]  

  • 7. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.
    Chen E; Tong KB; Malin JL
    Am J Manag Care; 2010 Dec; 16(12):e333-42. PubMed ID: 21291290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis.
    Norum J; Olsen JA; Wist EA; Lønning PE
    Acta Oncol; 2007; 46(2):153-64. PubMed ID: 17453363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 11. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
    Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
    Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective.
    Bines J; Eniu A
    Cancer; 2008 Oct; 113(8 Suppl):2353-8. PubMed ID: 18837028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine plus docetaxel combination therapy.
    Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; Martín M; McKendrick J; Miles D; Twelves C; Hornberger J
    Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
    Le QA; Hay JW
    Cancer; 2009 Feb; 115(3):489-98. PubMed ID: 19117341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of therapies for melanoma.
    Johnston KM; McPherson E; Osenenko K; Vergidis J; Levy AR; Peacock S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):229-42. PubMed ID: 25703441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit of the 21-gene breast cancer recurrence score assay for patients in Singapore.
    de Lima Lopes G; Chien R; Hornberger J
    Breast J; 2013; 19(2):220-1. PubMed ID: 23320386
    [No Abstract]   [Full Text] [Related]  

  • 19. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
    Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
    J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.
    Dixon S; Walters SJ; Turner L; Hancock BW
    Br J Cancer; 2006 Feb; 94(4):492-8. PubMed ID: 16449995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.